Corresponding author's email: paul.germonpre@uza.be : Epithelial growth factor receptor tyrosine kinase inhibitors (EGFR TKI) are the preferred first-line treatment in metastatic RATIONALE non-small cell lung cancer (NSCLC) patients whose tumor harbors an activating EGFR mutation. Such a personalized treatment requires that the EGFR mutation testing be carried out in a timely fashion. The aim of the Hermes project was to implement the centralized EGFR mutation testing in daily practice in the hospitals in the province of Antwerp and to determine the frequency of EGFR mutation in our Belgian population of NSCLC.
